Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Effects of a caspase and a calpain inhibitor on resting energy expenditures in normal and hypermetabolic rats: a pilot study

P. G. Vana, H. M. LaPorte, R. H. Kennedy, R. L. Gamelli, M. Majetschak

. 2016 ; 65 (3) : 537-541. [pub] 20160412

Language English Country Czech Republic

Document type Journal Article

Several diseases induce hypermetabolism, which is characterized by increases in resting energy expenditures (REE) and whole body protein loss. Exaggerated protein degradation is thought to be the driving force underlying this response. The effects of caspase and calpain inhibitors on REE in physiological and hypermetabolic conditions, however, are unknown. Thus, we studied whether MDL28170 (calpain inhibitor) or z-VAD-fmk (caspase inhibitor) affect REE under physiological conditions and during hypermetabolism post-burn. Rats were treated five times weekly and observed for 6 weeks. Treatment was started 2 h (early) or 48 h (late) after burn. In normal rats, MDL28170 transiently increased REE to 130 % of normal during week 2-4. z-VAD-fmk reduced REE by 20-25 % throughout the observation period. Within 14 days after burns, REE increased to 130+/-5 %. Whereas MDL28170/early treatment did not affect REE, MDL28170/late transiently increased REE to 180+/-10 % of normal by week 4 post-burn. In contrast, with z-VAD-fmk/early REE remained between 90-110 % of normal post-burn. z-VAD-fmk/late did not affect burn-induced increases in REE. These data suggest that caspase cascades contribute to the development of hypermetabolism and that burn-induced hypermetabolism can be pharmacologically modulated. Our data point towards caspase cascades as possible therapeutic targets to attenuate hypermetabolism after burns, and possibly in other catabolic disease processes.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17012738
003      
CZ-PrNML
005      
20170424110715.0
007      
ta
008      
170412s2016 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.933201 $2 doi
035    __
$a (PubMed)27070748
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Vana, P. G. $u Department of Surgery, Burn and Shock Trauma Research Institute, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA
245    10
$a Effects of a caspase and a calpain inhibitor on resting energy expenditures in normal and hypermetabolic rats: a pilot study / $c P. G. Vana, H. M. LaPorte, R. H. Kennedy, R. L. Gamelli, M. Majetschak
520    9_
$a Several diseases induce hypermetabolism, which is characterized by increases in resting energy expenditures (REE) and whole body protein loss. Exaggerated protein degradation is thought to be the driving force underlying this response. The effects of caspase and calpain inhibitors on REE in physiological and hypermetabolic conditions, however, are unknown. Thus, we studied whether MDL28170 (calpain inhibitor) or z-VAD-fmk (caspase inhibitor) affect REE under physiological conditions and during hypermetabolism post-burn. Rats were treated five times weekly and observed for 6 weeks. Treatment was started 2 h (early) or 48 h (late) after burn. In normal rats, MDL28170 transiently increased REE to 130 % of normal during week 2-4. z-VAD-fmk reduced REE by 20-25 % throughout the observation period. Within 14 days after burns, REE increased to 130+/-5 %. Whereas MDL28170/early treatment did not affect REE, MDL28170/late transiently increased REE to 180+/-10 % of normal by week 4 post-burn. In contrast, with z-VAD-fmk/early REE remained between 90-110 % of normal post-burn. z-VAD-fmk/late did not affect burn-induced increases in REE. These data suggest that caspase cascades contribute to the development of hypermetabolism and that burn-induced hypermetabolism can be pharmacologically modulated. Our data point towards caspase cascades as possible therapeutic targets to attenuate hypermetabolism after burns, and possibly in other catabolic disease processes.
650    _2
$a chloromethylketony aminokyselin $x farmakologie $x terapeutické užití $7 D000590
650    _2
$a zvířata $7 D000818
650    _2
$a popálení $x komplikace $7 D002056
650    _2
$a inhibitory kaspas $x farmakologie $x terapeutické užití $7 D061945
650    _2
$a inhibitory cysteinových proteinas $x farmakologie $x terapeutické užití $7 D015853
650    _2
$a dipeptidy $x farmakologie $x terapeutické užití $7 D004151
650    _2
$a preklinické hodnocení léčiv $7 D004353
650    _2
$a energetický metabolismus $x účinky léků $7 D004734
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a metabolické nemoci $x farmakoterapie $x etiologie $7 D008659
650    _2
$a pilotní projekty $7 D010865
650    _2
$a potkani Sprague-Dawley $7 D017207
655    _2
$a časopisecké články $7 D016428
700    1_
$a LaPorte, H. M. $u Department of Surgery, Burn and Shock Trauma Research Institute, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA
700    1_
$a Kennedy, R. H. $u Department of Molecular Pharmacology and Therapeutics, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA
700    1_
$a Gamelli, R. L. $u Department of Surgery, Burn and Shock Trauma Research Institute, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA
700    1_
$a Majetschak, M. $u Department of Surgery, Burn and Shock Trauma Research Institute, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA; Department of Molecular Pharmacology and Therapeutics, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 65, č. 3 (2016), s. 537-541
856    41
$u http://www.biomed.cas.cz/physiolres/ $y domovská stránka časopisu
910    __
$a ABA008 $b A 4120 $c 266 $y 4 $z 0
990    __
$a 20170412 $b ABA008
991    __
$a 20170421080801 $b ABA008
999    __
$a ok $b bmc $g 1201673 $s 973511
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 65 $c 3 $d 537-541 $e 20160412 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
LZP    __
$b NLK118 $a Pubmed-20170412

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...